secwatch.observer — SEC 8-K summary
======================================

Issuer:     PALVELLA THERAPEUTICS, INC. (PVLA)
CIK:        0001583648
Form:       8-K
Filed at:   2024-07-24T23:59:59+00:00
Accession:  0001437749-24-023301
Event type: m_and_a
Sentiment:  neutral
Materiality: 0.90
Item codes: 1.01, 3.02, 5.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Pieris to merge with Palvella in all-stock deal; Palvella holders to own 82%; PIPE raises $78.9M
--------------------------------------------------------------------------------

- Merger values Pieris at ~$21M and Palvella at ~$95M; pre-PIPE, Pieris stockholders hold ~18% of combined company.
- PIPE financing of ~$78.9M led by BVF Partners; investors buy ~3.15M shares plus pre-funded warrants.
- Each Pieris share receives one CVR entitling holders to future milestones/royalties from legacy partnered assets.
- Chief Development Officer Shane Olwill to depart effective Oct 31, 2024; receives €417,800 severance.
- Combined board to have 5 directors: 4 from Palvella (Kaupinen, Davis, Jenkins, Wessel), 1 from Pieris (Kiritsy).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1583648/000143774924023301/0001437749-24-023301-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1583648/000143774924023301/pirs20240722_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-24-023301

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer